Tangram Therapeutics announces progression in Phase 1/2 Trial of TGM-312 and CDO appointment
Tangram Therapeutics, a company committed to unlocking transformative RNAi medicines for meaningful patient impact, today announced progression of its MASH investigational treatment TGM-312 into Part B of the ongoing Phase 1/2 RESTORE-MASH trial. Tangram also announced the appointment of Dr Sonya Montgomery as Chief Development Officer to lead the advancement of the Company's clinical pipeline.
MASH is a common liver condition, affecting an estimated 250 million people globally and causing significant morbidity and mortality.1 Despite recent approvals in the space, substantial unmet need remains for efficacious treatments with good tolerability and lower patient burden.
TGM-312, an investigational GalOmic siRNA targeting SLC25A5, has a dual mode of action that directly impacts inflammation and steatosis, the key drivers of MASH and other chronic liver conditions. The target was discovered in-house using Tangram’s proprietary network biology approach in combination with MASH/MASLD population genetic data.
TGM-312’s liver-directed mechanism is designed to minimize systemic side effects, offering a patient-friendly, infrequently dosed treatment option. As demonstrated in extensive preclinical studies, TGM-312 holds broad potential both as monotherapy and in synergistic combination with approved and emerging approaches, due to its orthogonal mechanism of action.
TGM-312 is currently being evaluated in the Phase 1/2 RESTORE-MASH trial. Following favorable independent Data Monitoring Committee review, the trial has progressed from single ascending dose (SAD) in healthy volunteers to multiple ascending dose (MAD) in MASH patients. TGM-312 has been dosed across four cohorts of healthy volunteers to date with no serious or severe adverse events, de-risking both its novel mechanism of action and Tangram's proprietary GalOmic chemistry more broadly. Interim MASH patient data are anticipated during 2027.
Dr Sonya Montgomery brings over 25 years' experience designing and executing portfolio and development strategies, from translational research through registration. Her work spans a wide range of therapeutic areas and modalities, including genetic medicines, across both pharma and biotech. Following her training in engineering and medicine in Canada, Dr Montgomery held global leadership positions at Pfizer and has subsequently served as Vice President Clinical Development at ProQR, Vice President and Head of Clinical Development at Gyroscope Therapeutics, Chief Medical Officer at Evox Therapeutics, and, most recently, Chief Development Officer at OSE Immunotherapeutics.
Dr Laura Roca-Alonso, Interim Chief Executive Officer, said:
The progression of TGM-312 into MASH patient cohorts marks an important step forward for Tangram and reflects the strength of our GalOmic platform and the dedication of our team. Sonya's appointment comes at exactly the right time to build on this momentum, and her broad experience will be invaluable as we continue to advance our programs towards and through the clinic.
Dr Sonya Montgomery said:
I am pleased to join Tangram at this pivotal moment for the company. TGM-312 has the potential to make a meaningful difference for people living with MASH, and I'm looking forward to helping drive its development, as well as progressing Tangram’s broader innovative pipeline, including TGM-148 for bleeding disorders.
